Monte Rosa Therapeutics, Inc. (GLUE)

NASDAQ: GLUE · IEX Real-Time Price · USD
10.50
+1.34 (14.63%)
Aug 12, 2022 1:36 PM EDT - Market open

Balance Sheet (Trailing)

Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Quarter Ending 2022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-31
Cash & Equivalents
143.64351.41368.76358.79169.642.86---9.25
Short-Term Investments
178.8600000---0
Cash & Cash Equivalents
322.5351.41368.76358.79169.642.860009.25
Cash Growth
90.15%719.84%---363.63%----
Other Current Assets
--1.76-2.110.73---0.51
Total Current Assets
320.37348.67370.52358.29171.7143.59---9.76
Property, Plant & Equipment
20.3112.3311.88.927.734.62---1.34
Other Long-Term Assets
5.335.341.731.731.161.16---0
Total Long-Term Assets
25.6417.6613.5310.658.95.79---1.34
Total Assets
346.01366.33384.05368.94180.649.38---11.09
Accounts Payable
4.516.563.537.467.337.07---3.2
Current Debt
1.5200000---0.75
Other Current Liabilities
6.4610.089.213.331.7722.21---0.35
Total Current Liabilities
12.4916.6412.7410.799.0929.28---4.29
Long-Term Debt
5.4600000---0
Other Long-Term Liabilities
2.182.1821.470.961.07----
Total Long-Term Liabilities
7.642.1821.470.961.07---0
Total Liabilities
20.1318.8114.7412.2610.0530.34---4.29
Total Debt
6.9800000---0.75
Common Stock
473.98471.57469.85436.850.660.410000.05
Retained Earnings
-145.97-122.04-98.6-78.76-60.35-48.08----12.2
Comprehensive Income
-2.13-2.02-1.95-1.42-0.92-1.06---0
Shareholders' Equity
325.88347.52369.31356.68-60.62-48.73----12.15
Total Liabilities and Equity
346.01366.33384.05368.94-50.57-18.39000-7.86
Net Cash / Debt
315.52351.41368.76358.79169.642.860008.5
Net Cash / Debt Growth
86.03%719.84%---404.57%----
Net Cash Per Share
6.7714.068.0270.7699.2328.26---1.70
Working Capital
307.88332.03357.78347.5162.6214.32---5.47
Book Value Per Share
6.9913.908.0370.34-35.46-32.12----2.43
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).